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OBJECTIVE — Reasons for failing to initiate prescribed insulin (primary nonadherence) are
poorly understood. We investigated barriers to insulin initiation following a new prescription.
RESEARCH DESIGN AND METHODS — We surveyed insulin-naïve patients with
poorlycontrolledtype2diabetes,alreadytreatedwithtwoormoreoralagentswhowererecently
prescribed insulin. We compared responses for respondents prescribed, but never initiating,
insulin (n  69) with those dispensed insulin (n  100).
RESULTS — Subjects failing to initiate prescribed insulin commonly reported misconcep-
tions regarding insulin risk (35% believed that insulin causes blindness, renal failure, amputa-
tions, heart attacks, strokes, or early death), plans to instead work harder on behavioral goals,
sense of personal failure, low self-efﬁcacy, injection phobia, hypoglycemia concerns, negative
impact on social life and job, inadequate health literacy, health care provider inadequately
explaining risks/beneﬁts, and limited insulin self-management training.
CONCLUSIONS — Primaryadherenceforinsulinmaybeimprovedthroughbetterprovider
communication regarding risks, shared decision making, and insulin self-management training.
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I
nsulin is typically recommended for
patients with type 2 diabetes if they
have failed to achieve adequate glyce-
mic control despite treatment with multi-
ple oral agents at maximal dose (1),
especially when -cell function declines
(2,3). Despite the known beneﬁts of insu-
lin, many patients fail to begin insulin
treatment (4). In a previous study (5), we
followed a cohort of patients with diabe-
tes who were prescribed new glucose-
lowering medications. We observed that
4.5% of insulin-naïve patients who were
prescribed insulin never ﬁlled that pre-
scription (were primary nonadherent)
and an additional 25.5% had zero reﬁlls
(early-stagenonpersistence).Thus,onein
three insulin-naïve patients who were
prescribed insulin never became ongoing
users.
A patient’s reluctance to initiate insu-
linhasbeendubbedpsychologicalinsulin
resistance (PIR) (6). Current understand-
ing of PIR is based largely on surveys of
insulin-naïve patients queried about their
hypotheticalwillingnesstoinitiateinsulin
(7,8). However, the reasons why patients
fail to initiate therapy after actually agree-
ingtoandreceivingaﬁrstprescriptionfor
insulin have not been explored. In this
study, we evaluate barriers and attitudes
among insulin-naïve patients who had
failed to initiate newly prescribed insulin
therapy (i.e., primary nonadherent) ver-
sus those who did initiate insulin therapy
(i.e., primary adherent).
RESEARCH DESIGN AND
METHODS— Subjects for this study
of insulin adherence came from Kaiser
Permanente Northern California (Kaiser)
and Horizon Blue Cross Blue Shield of
New Jersey and were participants in the
Translating Research Into Action for Dia-
betes (TRIAD) Study (7), an ongoing
study of quality of care and self-care for
peoplewithdiabetesinmanaged-careset-
tings across the U.S.
We identiﬁed poorly controlled, in-
sulin-naïve and insulin-eligible type 2 di-
abetic patients receiving a new electronic
prescriptionforinsulin.Eligibilitycriteria
included1)newlyprescribedinsulindur-
ing August 2007 to February 2008, 2)
Twoormorediagnosesfortype2diabetes
18 months prior to the new insulin pre-
scription, 3) no insulin use in prior 2
years, 4) already taking one oral agent at
maximumandasecondoralagentatmax-
imal/submaximal dose, 5) two consecu-
tive A1Cs 8% 2.5–12 months apart or
last A1C 9%, and 6) two or more clinic
visits in the previous 12 months. Patients
aged85years,withlimitedEnglishpro-
ﬁciency, life-limiting malignancy, hos-
picecareenrollment,signiﬁcantcognitive
deﬁcits,psychiatricillness(excludingma-
jordepression),orvisualimpairmentlim-
iting insulin self-administration, were
excluded.
We identiﬁed a random sample of el-
igible subjects who were primary adher-
ent(atleastonedispensingofinsulin)and
primary nonadherent (not dispensed the
newly prescribed insulin within 60 days
of the prescribing date) from pharmacy
records. Computer-assisted telephone in-
terviews and self-administered mailed
surveys were used to collect insulin treat-
ment, provider communication, self-
management training, health literacy (8),
and depressive symptoms (9). We used
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for calculating response rates (10). The
human subjects review boards in the
TRIAD translational research centers in-
volved with this study (Kaiser, the Uni-
versity of Medicine and Dentistry of New
Jersey, and Indiana University) approved
this study.
RESULTS— We mailed an invitation
letter to 195 and 186 primary nonadher-
ent and adherent subjects, respectively,
followingapprovaloftheirproviders.Six-
ty-nine nonadherent and 100 adherent
patients responded to the survey and are
the basis for this study. The AAPOR re-
sponse rate, which assumes that those
who could not be contacted for eligibility
conﬁrmation had the same proportion of
eligibility as those contacted, was 60%
overall(50%inthenonadherentand68%
in adherent group). The cooperation rate
(percent survey completion among eligi-
ble subjects we were able to reach) was
98% (100% in the nonadherent and 92%
in adherent group). None of the patient
characteristics differed signiﬁcantly be-
tween adherent and nonadherent sub-
jects. Nonadherent subjects had a mean
age of 61 years and 35% were women,
49% were of a minority ethnic heritage,
37% had an income $40,000, 33% had
no college education, and 48% were re-
tired or unemployed. Adherent subjects
had a mean age of 58 years and 47% were
women,54%wereofminorityethnicher-
itage, 22% had an income $40,000,
31% had no college education, and 33%
were retired or unemployed.
Among nonadherent patients, the
most commonly cited reasons for failing
to initiate insulin included the following
reasons: The patient planned to change
health behaviors instead of starting in-
sulin (25%), injection phobia (13%),
negative impact on work (9%), con-
cerns about long-term medication use
(9%), inconvenience (6%), and not be-
lieving insulin was needed (6%). Non-
adherent patients believed that people
who require insulin “have not taken
care of themselves in the past” (47%)
and that “taking insulin can cause…”
blindness (20%), renal failure (32%),
amputations (15%), heart attacks or
strokes (19%), and early death (19%).
In all, 35% of the insulin-nonadherent
group reported that they believed insu-
lin causes harm (at least one of the pos-
sible complications listed above).
Compared with adherent patients,
nonadherent patients expressed signiﬁ-
cantly more concern about their inability
to adjust insulin dosage, the impact on
social life and work, injection pain, and
side effects, particularly hypoglycemia
(Table 1). Signiﬁcantly more nonadher-
ent patients reported problems learning
about their medical condition because of
difﬁculty understanding written informa-
tion (inadequate health literacy) and
claimed providers failed to adequately ex-
plain insulin’s risk and beneﬁts. Substan-
tially fewer nonadherent patients reported
receiving insulin self-management training
from their doctor, nurse, health educator,
or a class.
CONCLUSIONS— Among poorly
controlled patients with type 2 diabetes
newly prescribed insulin, the major pre-
dictors of insulin nonadherence included
plans to improve health behaviors in lieu
of starting insulin, negative impact on so-
cial and work life, injection phobia, and
concerns about side effects or hypoglyce-
mia. Nonadherent patients often blamed
themselves, believing prior poor self-
management caused the current need for
insulin and erroneously conceptualized
insulin as itself the cause of future com-
plications. These patient-level ﬁndings
are consistent with previous studies of at-
titudes about insulin (11,12).
Not previously reported is our ﬁnd-
ing that nonadherent patients frequently
felt their provider had not adequately ex-
plained the risks and beneﬁts of insulin.
The importance of provider communica-
tion is underscored by the association be-
tween insulin initiation and health
literacy (13). Primary nonadherence
Table 1—Comparisons of survey responses for primary nonadherent and adherent patients
newly prescribed insulin*
Nonadherent Adherent
Stated moderate/extreme concerns (versus not at all or a
little concerned) regarding:
The cost of insulin shots 12/51 (24) 22/82 (27)
How insulin shots might restrict your activities or “hold
back” your lifestyle 20/54 (37) 20/82 (24)
The additional burden associated with home monitoring
of blood sugar 15/59 (25) 19/82 (23)
Difﬁculty giving insulin due to things like poor eyesight,
shakiness, or arthritis 23/55 (42) 24/81 (30)
Your ability to make dose adjustments† 22/54 (41) 10/82 (12)
How insulin shots may negatively impact your social life† 21/56 (38) 15/82 (18)
A negative impact on your job (if you work outside the
home)† 15/45 (33) 6/72 (8)
The insulin shots being painful† 17/56 (30) 12/82 (15)
Possible side effects of giving yourself shots† 24/55 (44) 10/81 (12)
Insulin shots causing you to have low blood glucose† 22/51 (43) 13/81 (16)
Patient-provider interactions and communication
Never or only sometimes (versus usually or always) felt
conﬁdence or trust in personal physician that manages
diabetes 11/68 (16) 11/97 (11)
Moderately or extremely difﬁcult (versus not at all
difﬁcult or a little difﬁcult) to talk with doctor about
concerns about diabetes medication or insulin 9/66 (14) 10/100 (10)
Risks and beneﬁts were not very well or not well at all
(versus somewhat well or very well) explained† 37/67 (55) 37/96 (39)
Inadequate health literacy: sometimes, often, or always
(versus never or rarely); have problems learning about
medical condition because of difﬁculty understanding
written information (not including problems due to
poor vision)† 35/69 (51) 30/99 (30)
How was the insulin self-management training provided
Doctor trained† 1/66 (2) 13/77 (17)
Insulin self-management class† 5/66 (8) 31/77 (40)
Nurse trained† 4/66 (6) 33/77 (43)
Data are n/N (%). *N takes into account missing responses. †Signiﬁcant contrasts (P  0.05).
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cisionmakingorlackofself-management
training.InterventionsforPIRneedtoad-
dressbothprovider-andsystem-levelfac-
tors (14–16).
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